Collectively, ARID1A deficiency upregulates fatty acid metabolism to accelerate pancreatic tumourigenesis and FASN is a potential therapeutic target for ARID1A‐deficient pancreatic cancer. Here, FASN is linked to familial pancreatic carcinoma.